학술논문
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Document Type
Article
Author
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Gilson, Clare; Rush, Hannah; Bowen, Jo; Lydon, Anna; Pedley, Ian; O'Sullivan, Joe M; Birtle, Alison; Gale, Joanna; Srihari, Narayanan; Thomas, Carys; Tanguay, Jacob; Wagstaff, John; Das, Prantik; Gray, Emma; Alzoueb, Mymoona; Parikh, Omi; Robinson, Angus; Syndikus, Isabel; Wylie, James; Zarkar, Anjali; Thalmann, George; de Bono, Johann S; Dearnaley, David P; Mason, Malcolm D; Gilbert, Duncan; Langley, Ruth E; Millman, Robin; Matheson, David; Sydes, Matthew R; Brown, Louise C; Parmar, Mahesh K B; James, Nicholas D; Jones, Elin; Hyde, Katherine; Glen, Hilary; Needleman, Sarah; McGovern, Ursula; Sheehan, Denise; Paisey, Sangeeta; Shaffer, Richard; Beresford, Mark; Malik, Zafar; Zarkar, Anjali; Porfiri, Emilio; Fackrell, David; Lee, Ling; Sreenivasan, Thiagarajan; Brock, Sue; Brown, Simon; Bahl, Amit; Smith-Howell, Mike; Woodward, Cathryn; Phan, Mau-Don; Mazhar, Danish; Narahari, Krishna; Tanguay, Jacob; Douglas, Fiona; Kumar, Anil; Hamid, Abdel; Ibrahim, Azman; Muthukumar, Dakshinamoorthy; Simms, Matthew; Worlding, Jane; Tran, Anna; Kagzi, Mohammed; Das, Prantik; Pezaro, Carmel; Sivoglo, Virgil; Masters, Benjamin; Keng-Koh, Pek; Manetta, Caroline; McLaren, Duncan; Gupta, Nishi; Sheehan, Denise; Boussios, Stergios; Taylor, Henry; Graham, John; Perna, Carla; Melcher, Lucinda; Grant, Warren; Hyde, Katherine; Sabharwal, Ami; Hofmann, Uschi; Dealey, Robert; McPhail, Neil; Brierly, Robert; Brown, Simon; Capaldi, Lisa; Sidek, Norma; Whelan, Peter; Sreenivasan, Thiagarajan; Robson, Peter; Falconer, Alison; Rudman, Sarah; Vivekanandan, Sindu; Mullessey, Vinod; Needleman, Sarah; Vilarino-Varela, Maria; Khoo, Vincent; Tipples, Karen; Afshar, Mehran; Falconer, Alison; Brulinski, Patryk; Sangar, Vijay; Peedell, Clive; Azzabi, Ashraf; Hoskin, Peter; Mullassery, Viwod; Sundar, Santhanam; Khan, Yakhub; Conroy, Ruth; Protheroe, Andrew; Carser, Judith; Rogers, Paul; Capaldi, Lisa; Tarver, Kathryn; Gibbs, Stephanie; Khan, Mohammad Muneeb; Hingorani, Mohan; Azzabi, Ashraf; Crabb, Simon; Alameddine, Manal; Bhalla, Neeraj; Manetta, Caroline; Hughes, Robert; Logue, John; Leaning, Darren; Vengalil, Salil; Azzabi, Ashraf; Ford, Daniel; Walker, Georgina; Shaheen, Ahmed; Khan, Omar; Chan, Andrew; Ahmed, Imtiaz; Hilman, Serena; Douglas, Fiona; Kumar, Anil; Tran, Anna; Paisey, Sangeeta; Sayers, Ian; Capaldi, Lisa; Nikapota, Ashok; Bloomfield, David; Porter, Tim; Joseph, Joji; Rentsch, Cyrill; Pereira Mestre, Ricardo; Roggero, Enrico; Beyer, Jörg; Borner, Markus; Strebel, Raeto; Berthold, Dominik; Engeler, Daniel; John, Hubert; Popescu, Razvan; Durr, Donat
Source
The Lancet; January 2022, Vol. 399 Issue: 10323 p447-460, 14p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population.